Humanigen Inc (HGENQ)

[DonDonDonDon]

The new May presentation is posted on Humanigen's site. Take a look at slide 15. In the group that had a CRP<150mg/L + <85yo + remdesivir, the mortality rate in the placebo arm was 17.3% and the mortality rate in the lenz arm was 7.5%. That is the exact group that is now the primary endpoint population of the ACTIV trial. That is bonkers mortality efficacy! Stat sig on mortality is possible or even likely in the ACTIV trial. Stat sig on mortality could push HGEN's share price north of $30!

https://s28.q4cdn.com/539885110/files/doc_presentations/2022/LSX-World-Congress-May-10-2022.pdf